Literature DB >> 11176459

Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts.

R J Stewart1, D Panigrahy, E Flynn, J Folkman.   

Abstract

PURPOSE: The hormonally regulated growth of some human carcinomas represents an important therapeutic target. We report that androgens modulate the angiogenic activity of hormone responsive human prostate cancer.
MATERIALS AND METHODS: To define further the critical mechanisms underlying hormone responsiveness we examined the angiogenic mediator, vascular endothelial growth factor messenger (m) RNA and protein in response to androgens in vitro as well as the angiogenic response of xenografts of human prostate cancer after androgen withdrawal in vivo.
RESULTS: In vitro androgen deprivation of LnCaP prostate cancer cells led to decreased vascular endothelial growth factor mRNA and protein expression as well as a 5-fold destabilization in vascular endothelial growth factor mRNA transcripts. In addition, androgen withdrawal inhibited the hypoxic induction of vascular endothelial growth factor mRNA. In mice bearing LnCaP tumors castration resulted in a rapid decrease in mRNA expression and markedly reduced tumor neovascularization.
CONCLUSIONS: These findings implicate sex steroids as an important stimulus for vascular endothelial growth factor regulation in hormone sensitive tumors and demonstrate the reversal of neovascularization after hormone withdrawal as an early event in the tumor response to therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176459     DOI: 10.1097/00005392-200102000-00095

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  31 in total

1.  Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.

Authors:  Kylie Graham; Wenliang Li; Bryan R G Williams; Gail Fraizer
Journal:  Gene Expr       Date:  2006

2.  Vascular endothelial growth factor and angiopoietin are required for prostate regeneration.

Authors:  Gui-Min Wang; Bruce Kovalenko; Yili Huang; David Moscatelli
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

3.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

Review 4.  Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis.

Authors:  M Ghashghaei; M Kucharczyk; S Elakshar; T Muanza; T Niazi
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

5.  Increased endothelial progenitor cells and vasculogenic factors in higher-staged arteriovenous malformations.

Authors:  Lingge Lu; Joyce Bischoff; John B Mulliken; Diane R Bielenberg; Steven J Fishman; Arin K Greene
Journal:  Plast Reconstr Surg       Date:  2011-10       Impact factor: 4.730

6.  Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Authors:  Kwanghee Kim; Philip A Watson; Souhil Lebdai; Sylvia Jebiwott; Alexander J Somma; Stephen La Rosa; Dipti Mehta; Katie S Murray; Hans Lilja; David Ulmert; Sebastien Monette; Avigdor Scherz; Jonathan A Coleman
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

7.  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.

Authors:  Vassiliki Tzelepi; Eleni Efstathiou; Sijin Wen; Patricia Troncoso; Maria Karlou; Curtis A Pettaway; Louis L Pisters; Anh Hoang; Christopher J Logothetis; Lance C Pagliaro
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

8.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

9.  Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.

Authors:  Juan Wen; Yuan Zhao; Jinghe Li; Chunyan Weng; Jingjing Cai; Kan Yang; Hong Yuan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2013-02-19       Impact factor: 4.104

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.